Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boston, MA
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Columbus, OH
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Oklahoma City, OK
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Seattle, WA
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
mi
from
Klagenfurt,
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
mi
from
Klagenfurt,
Click here to add this to my saved trials
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  11/25/2015
Fairview Cancer Hospital
mi
from
Cleveland, OH
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 11/25/2015
Fairview Cancer Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  11/25/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 11/25/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  11/25/2015
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 11/25/2015
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Emory University Hospital
mi
from
Atlanta, GA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation
Status: Enrolling
Updated:  12/1/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation
Status: Enrolling
Updated: 12/1/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2015
Tufts Medical Center
mi
from
Boston, MA
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2015
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated:  12/2/2015
Clinical Research Facility
mi
from
Orange, CA
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated: 12/2/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated:  12/2/2015
Clinical Research Facility
mi
from
Aurora, CO
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated: 12/2/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated:  12/2/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated: 12/2/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated:  12/2/2015
Clinical Research Facility
mi
from
Portland, OR
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis
Status: Enrolling
Updated: 12/2/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Status: Enrolling
Updated:  12/3/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Status: Enrolling
Updated: 12/3/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias
Status: Enrolling
Updated:  12/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias
Status: Enrolling
Updated: 12/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age
Status: Enrolling
Updated:  12/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age
Status: Enrolling
Updated: 12/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  12/3/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 12/3/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  12/3/2015
Vanderbilt University
mi
from
Nashville, TN
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 12/3/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma
Status: Enrolling
Updated:  12/3/2015
Veteran's Administration Medical Center
mi
from
Las Angeles, CA
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma
Status: Enrolling
Updated: 12/3/2015
Veteran's Administration Medical Center
mi
from
Las Angeles, CA
Click here to add this to my saved trials
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease
Status: Enrolling
Updated:  12/4/2015
University of Michigan
mi
from
Ann Arbor, MI
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease
Status: Enrolling
Updated: 12/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated:  12/4/2015
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated: 12/4/2015
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated:  12/4/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated: 12/4/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated:  12/4/2015
Weill-Cornell Medical College
mi
from
New York, NY
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Status: Enrolling
Updated: 12/4/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Status: Enrolling
Updated:  12/4/2015
Vanderbilt University
mi
from
Nashville, TN
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Status: Enrolling
Updated: 12/4/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Measurement of Platelet Dense Granule Release in Healthy Volunteers
Measurement of Platelet Dense Granule Release in Healthy Volunteers
Status: Enrolling
Updated:  12/4/2015
Vanderbilt University
mi
from
Nashville, TN
Measurement of Platelet Dense Granule Release in Healthy Volunteers
Measurement of Platelet Dense Granule Release in Healthy Volunteers
Status: Enrolling
Updated: 12/4/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/8/2015
University of Iowa Hospitals
mi
from
Iowa City, IA
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/8/2015
University of Iowa Hospitals
mi
from
Iowa City, IA
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Pinnacle Oncology
mi
from
Scottsdale, AZ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Pinnacle Oncology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Northwestern University
mi
from
Chicago, IL
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
Status: Enrolling
Updated:  12/9/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
Status: Enrolling
Updated: 12/9/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.
Status: Enrolling
Updated:  12/9/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.
Status: Enrolling
Updated: 12/9/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/10/2015
Northside Hospital
mi
from
Atlanta, GA
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/10/2015
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Status: Enrolling
Updated:  12/10/2015
Colorado Blood Cancer Institute
mi
from
Denver, CO
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Status: Enrolling
Updated: 12/10/2015
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Status: Enrolling
Updated:  12/10/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Status: Enrolling
Updated: 12/10/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials